



POSTER PRESENTATION

Open Access

Detection of antibodies to the $\alpha 4\beta 7$ integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay

M Rao^{1*}, N Karasavvas², A Pinter³, H Liao⁴, M Bonsignori⁴, B Mathieson⁵, S Zolla-Pazner⁶, BF Haynes⁴, NL Michael¹, JH Kim¹, CR Alving¹, KK Peachman⁷

From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012

Background

The gut mucosal homing integrin receptor $\alpha 4\beta 7$ present on activated CD4+ T-cells interacts with the HIV-1 gp120 second variable loop (V2). Case control analysis of the RV144 phase III vaccine trial showed that antibodies induced by the vaccine bound to a MuLV-gp70 scaffolded V1V2 loop of gp120 (V1V2-gp70) and correlated inversely with infection. These, and other data, generate the hypothesis that the vaccine-elicited antibodies may have been involved in limiting HIV-1 acquisition. We have developed a high-throughput assay to evaluate antibodies that block $\alpha 4\beta 7$ binding. We have named this the RAP assay.

Methods

Plates were coated with either MAdCAM-1, the natural ligand of $\alpha 4\beta 7$, or streptavidin followed by the addition of biotinylated cyclic-V2 peptides (strain 92TH023 or MN). Plasma and purified IgG antibodies from RV144 volunteers, conformational mAbs specific for V2 (697), for V2 and V3 (PG9, PG16), or for V2 linear epitopes (CH58 and CH59, cloned from RV144 vaccinee B cells) were then added to the peptide-coated plates followed by RPMI8866 cells, which constitutively express $\alpha 4\beta 7$. Cell binding/inhibition was assessed by AlamarBlue. Anti- $\alpha 4\beta 7$ -specific mAb (ACT-1) served as a control. In separate experiments, plasma, IgG, or mAbs were tested in a competition assay using V1V2-gp70.

Results

ACT-1 inhibited the binding of both MAdCAM-1 and cyclic-V2 peptides to $\alpha 4\beta 7$ by 65-85%, while CH58 and

CH59 inhibited the $\alpha 4\beta 7$ -cyclic-V2 peptide binding by 37-45% in a dose-dependent manner. PG9, PG16, and 697 did not inhibit the binding of V2-peptides to the cells. However, in the competition assay, 697 and PG9 mAbs inhibited V1V2-gp70 binding to $\alpha 4\beta 7$. Some of the RV144 plasma and IgG inhibited binding to 92TH023 or MN-V2-peptides.

Conclusion

We have developed a novel high-throughput reproducible assay for assessing $\alpha 4\beta 7$ -specific blocking antibodies. The above results raise the hypothesis that anti-V2 loop antibodies may play a role in regulation of gp120- $\alpha 4\beta 7$ interaction.

Author details

¹U.S. Military HIV Research Program, WRAIR, Silver Spring, MD, USA. ²Armed Forces Research Institute of Medical Science (AFRIMS), Bangkok, Thailand. ³The Public Health Research Institute Center at the International Centre, Newark, NJ, USA. ⁴Duke Human Vaccine Institute Duke University Medical Center, Durham, NC, USA. ⁵Office of AIDS Research, National Institutes of Health, Bethesda, MD, USA. ⁶NYU School of Medicine, New York, NY, USA. ⁷United States Military HIV Research Program, WRAIR / HJF, Silver Spring, MD, USA.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P71

Cite this article as: Rao et al.: Detection of antibodies to the $\alpha 4\beta 7$ integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay. *Retrovirology* 2012 **9**(Suppl 2):P71.

¹U.S. Military HIV Research Program, WRAIR, Silver Spring, MD, USA
Full list of author information is available at the end of the article